Drugs / Epoetin alfa Megalabs®
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06352138 | Jul 2025 → Mar 2027 expected | anemia due to chronic disorder | Megalabs | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epoetin alfa Megalabs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06352138 ↗ |
| Known as | Erythropoietin | “Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.” NCT06352138 ↗ |
| Modality | Protein / enzyme biologic | “Human recombinant epoetin alfa” NCT06352138 ↗ |